RESEARCH TRIANGLE PARK – G1 Therapeutics is expanding its own sales force to handle its recently FDA approved cancer treatment.
G1 (Nasdaq: GTHX) disclosed early Thursday that a co-promotion agreement with Boehringer Ingelheim will end next March. The decision was “mutually agreed” upon, G1 said in the announcement.
The drug, called Cosela, was approved by the FDA in February.
After 13 years of trials and tribulations RTP firm G1 wins first FDA approval for cancer drug
G1 said it will hire an additional 20 salespeople, bringing the company’s total to 34.
“We are well along in the process of hiring our COSELA-focused sales force; these experienced oncology sales professionals have existing relationships at target organizations and are prioritizing prescriber access, which is the key to execution and adoption of new therapies like Cosela,” said Andrew Perry, Chief Commercial Officer of G1, in a statement.
“Our goal is to drive as quick an impact as possible from this effort, and as such we are hiring, training, and deploying these individuals into the field as they arrive,” he added. “We have already hired 13 of these field-based professionals, deployed seven, and expect to have the full team of 34 in place and deployed by mid-February 2022.”
Triangle firm lands deal worth up to $310M for breast cancer treatment
